Evropska unija - islandščina - EMA (European Medicines Agency)

roche registration gmbh - atezolizumab - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - Æxlishemjandi lyf - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq eitt og sér er ætlað fyrir meðferð fullorðinn sjúklinga með staðnum háþróaður eða sjúklingum nsclc eftir áður en lyfjameðferð. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq eitt og sér er ætlað fyrir meðferð fullorðinn sjúklinga með staðnum háþróaður eða sjúklingum nsclc eftir áður en lyfjameðferð. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.

Evropska unija - islandščina - EMA (European Medicines Agency)

takeda france sas - mifamurtíð - osteosarcoma - Ónæmisörvandi, - mepact er ætlað í börn, unglingum og ungu fólki fyrir meðferð hágæða resectable ekki sjúklingum beinsarkmeina eftir macroscopically fylltu skurðaðgerð. Það er notað samhliða krabbameinslyfjameðferð eftir aðgerð. Öryggi og verkun hefur verið metið í rannsóknum á sjúklingum tveimur til 30 ára við fyrstu greiningu.

Islandija - islandščina - LYFJASTOFNUN (Icelandic Medicines Agency)

actavis group ptc ehf. - clozapinum inn - tafla - 25 mg

Islandija - islandščina - LYFJASTOFNUN (Icelandic Medicines Agency)

teva b.v.* - isosorbidi mononitras inn - forðatafla - 60 mg

Islandija - islandščina - LYFJASTOFNUN (Icelandic Medicines Agency)

orifarm healthcare a/s - glyceryli trinitras - tungurótartafla - 0,25 mg

Islandija - islandščina - LYFJASTOFNUN (Icelandic Medicines Agency)

orifarm healthcare a/s - glyceryli trinitras - tungurótartafla - 0,5 mg

Evropska unija - islandščina - EMA (European Medicines Agency)

roche registration gmbh - vismodegib - krabbamein, basalfrumur - Æxlishemjandi lyf - Þetta lyf er ætlað fyrir meðferð fullorðinn sjúklinga með:- einkennum sjúklingum grunn klefi krabbamein - staðnum háþróaður grunn klefi krabbamein óviðeigandi fyrir aðgerð eða geislameðferð.

Islandija - islandščina - LYFJASTOFNUN (Icelandic Medicines Agency)

actavis group ptc ehf. - epirubicinum hýdróklóríð - stungulyf, lausn - 2 mg/ml

Islandija - islandščina - LYFJASTOFNUN (Icelandic Medicines Agency)

ferring lægemidler a/s - progesteronum inn - leggangatafla - 100 mg

Evropska unija - islandščina - EMA (European Medicines Agency)

itm medical isotopes gmbh - lutetium (177lu) chloride - radionuclide imaging - heilsueyðandi lyf - endolucinbeta er geislavirkt forefni og er ekki ætlað til beinnar notkunar hjá sjúklingum. Það er einungis ætlað til geislamerktra flutningsfrumna sem hafa verið sérstaklega þróaðir og leyfð til geislamerktar með lúetítíum (177lu) klóríði.